Here's a bit more.
http://www.pharmalive.com/News/index...tegoryid=36,61
Quote:
|
Alvine's platform is based on over six years of research, and an extensive intellectual property portfolio licensed from Stanford University and acquired from the Celiac Sprue Research Foundation.
|
Quote:
|
"Celiac sprue is a serious yet common immune disease that is triggered by gluten, a component of cereal grains found in most foods sold in the U.S. While under-diagnosed, as many as one in one hundred individuals suffer from celiac sprue, yet there is no drug therapy available. Alvine's mission is to provide innovative drug therapies for this disease and to change the lives of its many patients," he continued.
|
as many as one in one hundred individuals suffer from celiac sprue, yet there is no drug therapy available.
Oh the horror...oh the humanity...
Hmmm, I wonder what the side effects will be?